Levosulpiride

Form: Oral tablets, capsules

Strength: 25 mg, 50 mg, 75 mg, 100 mg

Reference Brands: not approved in US/EU; Eastern European nations markets as Levopraid, Neoprad, or as generics.

Category: Antipsychotropic Drugs

Levosulpiride is a substituted benzamide antipsychotic and prokinetic agent used for dyspepsia, GERD, and psychiatric conditions such as depression and schizophrenia. Available in oral (25 mg, 50 mg, 75 mg) and injectable (25 mg/2 ml, 50 mg/2 ml) forms, Levosulpiride is marketed in select EU regions under brands like Levopraid and Neoprad. While not FDA-approved in the US, it is in demand across Asia, Eastern Europe, and Latin America. Pharma B2B buyers source Levosulpiride for therapeutic areas including GI motility and mood disorders. GMP-compliant manufacturers offer bulk supply solutions for hospitals, clinics, and global distributors.